Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8076746 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL31039441 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL29928092 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL9671669 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL18746891 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL13645501 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL5652054 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL8072599 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL27161205 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 | |
| SCHEMBL7535856 | 0.98 | DUT (0.38) | DUTTSHRALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2603098-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | Senomyx, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021837-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| EP-0679152-B1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES | COSMOS PHARM CORP (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0679152-A1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES. | LAFOR LAB LTD (US) | 1995-11-02 | — | — | EP | disclosed |
| EP-0399633-B1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AG (DE) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994015900-A1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES | LAFOR LABORATORIES LIMITED (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5264619-A | Anti-androgenic cyclo and bicyclo alkenes | LAFOR LABORATORIES LIMITED (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1990014329-A1 | LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-11-29 | — | — | WO | disclosed |
| EP-0399633-A1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | DUT 1587/4885ADRB2 161/4885ADRB1 75/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | DUT 2012/4885ADRB2 3417/4885ADRB1 3818/4885 |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | DUT 4087/4885ADRB2 416/4885ADRB1 328/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | DUT 2012/4885ADRB2 3417/4885ADRB1 3818/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | DUT 2012/4885ADRB2 3417/4885ADRB1 3818/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | DUT 482/4885ADRB2 4658/4885ADRB1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.